ALUMIS INC. (ALMS) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 16 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026after close 43 8-K
Q2 FY2026Thu, Aug 13, 2026after close 44 8-K
Q1 FY2026Thu, May 14, 2026after close 44 8-K
Q4 FY2025Thu, Mar 19, 2026after close 78 8-K
Q3 FY2025Thu, Nov 13, 2025after close 44 8-K
Q2 FY2025Wed, Aug 13, 2025after close 44 8-K
Q1 FY2025Wed, May 14, 2025after close 44 8-K
Q4 FY2024Wed, Mar 19, 2025after close 78 8-K

What they guided beta

Q3 FY2026 "EX-99.1 2 alms-ex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies – ​ – Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 – ​ –Announced topline results from the LUMUS Phase 2b " exhibit
Q3 FY2026 "Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. ​ Envudeucitinib: Systemic Lupus Erythematosus (SLE)" exhibit
Q3 FY2026 "Net loss was $94.9 million for the quarter ended September 30, 2026, compared to net loss of $110.8 million for the quarter ended September 30, 2025. ​ Financial Guidance" exhibit
Q3 FY2026 "Based on the Company’s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027. ​ About Alumis Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases." exhibit
Q2 FY2026 "EX-99.1 2 alms-20260813xex99d1.htm EX-99.1 ​ Exhibit 99.1 ​ ​ Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements ​ – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – ​ – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – ​ – Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 – ​ ​ SOUTH SAN FRANCISCO, Calif., August 13, 2026 – Alumi" exhibit
Q2 FY2026 "We remain on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 with the goal, if approved, of bringing this new oral treatment option to patients.” ​ “Looking ahead, our main focus is on realizing our two TYK2 pipeline-in-a-pill franchise opportunities.”" exhibit
Q2 FY2026 "Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in PsO in the fourth quarter of 2026." exhibit
Q2 FY2026 "Alumis anticipates potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE in the third quarter of 2026, a milestone with the potential to open the Type I interferon disease pathway for the TYK2 franchise. ​ TYK2 Franchise and Pipeline Update" exhibit
Q2 FY2026 "Next clinical candidate (new target) o Alumis now expects to initiate a clinical trial for the next clinical candidate in 2027 ​ Second Quarter 2026 Financial Results" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ALMS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ALMS

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ALMS earnings date badge

HTML

<a href="https://veritasdata.dev/company/ALMS/"><img src="https://veritasdata.dev/embed/ALMS.svg" alt="ALMS earnings date" width="240" height="56"></a>

Markdown

[![ALMS earnings date](https://veritasdata.dev/embed/ALMS.svg)](https://veritasdata.dev/company/ALMS/)

Script

<script async src="https://veritasdata.dev/embed/ALMS.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ALMS"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.